NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373

ID: 1520658
recent pressrelease next pressrelease

(Thomson Reuters ONE) -


Received Best Poster Presentation Award at ESMO 2017

EDINBURGH, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- NuCana plc
announced the presentation of interim first-in-human data from a Phase 1
clinical study of NUC-3373, its ProTide transformation of the active anti-cancer
metabolite of 5-fluorouracil (5-FU), at the European Society for Medical
Oncology (ESMO) 2017 Congress held earlier this week in Madrid, Spain.

Interim pharmacokinetic (PK) and pharmacodynamic (PD) data were presented at
ESMO 2017, and the presentation was awarded "Best Poster" status by the
organizing committee.  Key findings from the study included PK and PD data from
21 patients with 10 different advanced solid tumor cancer types and indicated
that NUC-3373 has the potential to have greater activity and an improved safety
profile as compared to 5-FU.  The results indicated a linear and reproducible
dose-response across all dose ranges as well as a well-tolerated safety
profile.  After a short administration, plasma half-life of NUC-3733 was 9.7
hours, as compared to the 8 to 14 minute half-life associated with 5-FU.
Evidence of rapid and efficient intracellular activity were noted, with high
levels of FUDR-MP, the active anti-cancer metabolite of 5-FU detectable in cells
5 minutes after infusion and still detectable after 48 hours.  NUC-3373 bound to
and inhibited the target enzyme, thymidylate synthase, and depleted the pool of
dTMP, a nucleotide necessary for DNA replication, 2 to 4 hours after
administration.  Additionally, NUC-3373 did not generate the key toxic
metabolites of 5-FU (F-BAL or dhFU) intracellularly or in the patient''s plasma.

"NUC-3373 appears to have considerable advantages over 5-FU, with much higher
levels of the active, anti-cancer metabolite, that may overcome key cancer
resistance pathways and allow for a more favourable safety profile and a more


convenient dosing regimen," said Dr. Sarah Blagden, Associate Professor of
Experimental Cancer Medicine at the University of Oxford and Chief Investigator
of the study. "5-FU remains one of the most important and widely used anti-
cancer drugs in the world.  This interim analysis of NUC-3373''s Phase 1 data
strongly supports its continued development."

Hugh Griffith, NuCana''s Chief Executive Officer, said: "NUC-3373 is our second
product candidate that uses our proprietary ProTide technology with the goal of
improving the efficacy and safety of important anti-cancer agents.  We are
excited to see these interim data and especially gratified that it was chosen
for a Best Poster award at ESMO 2017. These data support that NUC-3373 may have
a key role to play in the treatment of cancer and we look forward to continuing
its rapid development, along with the development of other product candidates in
our pipeline."

About NuCana

NuCana(®) is a clinical-stage biopharmaceutical company focused on significantly
improving treatment outcomes for cancer patients by applying our
ProTide((TM)) technology to transform some of the most widely prescribed
chemotherapy agents, nucleoside analogs, into more effective and safer
medicines. While these conventional agents remain part of the standard of care
for the treatment of many solid tumors, their efficacy is limited by cancer cell
resistance mechanisms and they are often poorly tolerated. Utilizing our
proprietary technology, we are developing new medicines, ProTides, designed to
overcome key cancer resistance mechanisms and generate much higher
concentrations of anti-cancer metabolites in cancer cells. Our most advanced
ProTide candidates, Acelarin(®) and NUC-3373, are new chemical entities derived
from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two
widely used chemotherapy agents. Acelarin is currently being evaluated in four
clinical studies across several solid tumor indications, including ovarian
cancer, biliary cancer and pancreatic cancer. NUC-3373 is currently in a Phase
1 study for the potential treatment of a wide range of advanced solid tumor
cancers.  For more information, please visit: www.nucana.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements that are based on
the beliefs and assumptions and on information currently available to management
of NuCana plc (the "Company"). All statements other than statements of
historical fact contained in this press release are forward-looking statements,
including statements concerning the initiation, timing, progress and results of
clinical trials of the Company''s product candidates. In some cases, you can
identify forward-looking statements by terminology such as "may," "will,"
"should," "expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these terms or other
comparable terminology.  Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the Company''s actual
results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking
statements. Forward-looking statements represent the Company''s beliefs and
assumptions only as of the date of this press release. Although the Company
believes that the expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity, performance
or achievements. Except as required by law, the Company assumes no obligation to
publicly update any forward-looking statements for any reason after the date of
this press release to conform any of the forward-looking statements to actual
results or to changes in its expectations.

For more information, please contact:

Hugh Griffith
Chief Executive Officer
+44 131 248 3660
info(at)nucana.com

Westwicke Partners
Chris Brinzey
+1 339-970-2843
Chris.brinzey(at)westwicke.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NuCana BioMed Limited via GlobeNewswire






More information:
http://www.pressreleasefinder.com/SABIC/SABICPR300/en/ http://www.pressreleasefinder.com/SABIC/SABICPR299/en/ http://www.BroadSoft.com https://www.addivant.com/ http://www.sofamania.com/collections/futon http://www.kesko.fi http://iconicbrandsusa.com htt



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: hugin
print pressrelease  send to a friend  

Date: 09/13/2017 - 07:00
Language: English
News-ID 1520658
Character count: 2094
Kontakt-Informationen:
Firma: NuCana BioMed Limited
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Edinburgh
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 186

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 8 016
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 49


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.